Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion

Fineline Cube Apr 26, 2024

China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off,...

Company Deals

Allgens Medical Technology to Acquire German Dental Implant Maker HumanTech Dental for EUR 3.25 Million

Fineline Cube Apr 26, 2024

Beijing-based Allgens Medical Technology Co., Ltd (SHA: 688613), specializing in regenerative medicine materials and implantable...

Company Drug

Wuhan Bio-Raid Biotechnology Secures NMPA Approval for First-in-Class CD99-Targeted CAR-T Therapy

Fineline Cube Apr 26, 2024

Wuhan Bio-Raid Biotechnology Co., Ltd, a leading developer of chimeric antigen receptor (CAR)-T cell therapies...

Company

Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023

Fineline Cube Apr 26, 2024

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its...

Company

JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva

Fineline Cube Apr 26, 2024

China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching...

Company

MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact

Fineline Cube Apr 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first...

Company

Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing

Fineline Cube Apr 26, 2024

China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with...

Company Deals

Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round

Fineline Cube Apr 26, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai...

Company

Huadong Medicine’s Lidocaine-Containing Hyaluronic Acid Gel Accepted for NMPA Review

Fineline Cube Apr 26, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Policy / Regulatory

China’s NHC to Assume Management of Human Genetic Resources from May 2024

Fineline Cube Apr 26, 2024

The National Health Commission (NHC) of China has announced that the State Council has approved...

Company Drug

Chia Tai Tianqing’s TQA3038 siRNA Drug Completes Phase I Clinical Trial for Chronic Hepatitis B

Fineline Cube Apr 26, 2024

Chia Tai Tianqing has announced the successful completion of a Phase I clinical study for...

Company Drug

US FDA Greenlights Henlius Biotech’s Hanquyou as Biosimilar to Roche’s Herceptin

Fineline Cube Apr 26, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has achieved a significant milestone with the US Food...

Company

Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches

Fineline Cube Apr 26, 2024

France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter...

Company Drug

Novartis Receives Positive Interim Results for Antimalarial Coartem in Infants

Fineline Cube Apr 26, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced interim results from a Phase II/III clinical...

Company

Bristol Myers Squibb Reports 6% YOY Revenue Growth in Q1 2024, Driven by Eliquis and Reblozyl

Fineline Cube Apr 26, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has reported a 6% year-on-year (YOY) increase...

Company

Roche’s Q1 2024 Turnover Rises 2% YOY, Driven by New Medicines and Diagnostics

Fineline Cube Apr 25, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has reported a 2% year-on-year (YOY) increase...

Company

Gan & Lee Pharmaceuticals Reports 52.31% YOY Revenue Growth in 2023, Driven by Insulin Sales

Fineline Cube Apr 25, 2024

Gan & Lee Pharmaceuticals (SHA: 603087) has announced its financial results for 2023, reporting a...

Company Policy / Regulatory

Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act

Fineline Cube Apr 25, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...

Company Deals

Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery

Fineline Cube Apr 25, 2024

China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with...

Company Drug

Hebei Changshan Biochemical’s Albenatide File for Type 2 Diabetes Accepted by China’s NMPA

Fineline Cube Apr 25, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) has announced that the National Medical...

Posts pagination

1 … 414 415 416 … 711

Recent updates

  • METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.